Related Experiment Video
Updated: May 17, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A
Chunfu Wang1, Lourdes Valera, Lingling Jia
1Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.
Abstract:
The NS5A replication complex inhibitor daclatasvir (DCV; BMS-790052) inhibits hybrid replicons containing hepatitis C virus (HCV) genotype 3a (HCV3a) NS5A genes with 50% effective concentrations (EC(50)s) ranging from 120 to 870 pM. Selection studies with a hybrid HCV3a replicon identified NS5A residues 31 and 93 as sites for DCV-selected resistance. Our results support the potential use of DCV as a component in combination therapies for HCV3a chronic infection.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis

